ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Historical Holders from Q1 2018 to Q3 2025

Symbol
RCKT on Nasdaq
CUSIP
77313F106
Type / Class
Equity / Common Stock, $0.01 par value per share
Shares outstanding
107M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
96.6M
Holdings value
$315M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
168
Number of buys
87
Number of sells
-110
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAVERICK CAPITAL LTD 7.8% +52% $28M $9.44M 8.36M +50.8% Maverick Capital, Ltd. Jun 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 0.9% -82.9% $7.9M -$48.3M 1M -86% Wellington Management Group LLP May 30, 2025

Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 96.6M $315M +$10.6M $3.26 168
2025 Q2 95M $233M -$148M $2.45 194
2025 Q1 108M $722M -$52.7M $6.67 233
2024 Q4 110M $1.38B +$165M $12.57 222
2024 Q3 92.5M $1.71B +$15.9M $18.47 189
2024 Q2 91.2M $1.96B -$31.8M $21.53 179
2024 Q1 92M $2.48B +$111M $26.94 187
2023 Q4 41.2K $1.25M -$748K $30.44 2
2023 Q3 89.1M $1.83B +$246M $20.49 172
2023 Q2 76.1M $1.51B -$36.1M $19.87 160
2023 Q1 78.2M $1.34B +$44.2M $17.13 158
2022 Q4 75.9M $1.49B +$146M $19.57 163
2022 Q3 69M $1.1B +$65.7M $15.96 154
2022 Q2 64.5M $887M +$4.03M $13.76 138
2022 Q1 62.5M $991M +$10.1M $15.86 138
2021 Q4 63.1M $1.38B +$9.18M $21.83 137
2021 Q3 61.5M $1.84B -$26M $29.89 140
2021 Q2 61.7M $2.73B -$54.4M $44.29 143
2021 Q1 61.9M $2.75B -$19.1M $44.37 169
2020 Q4 61.9M $3.39B +$435M $54.84 169
2020 Q3 55.1M $1.26B +$22.9M $22.86 121
2020 Q2 53.2M $1.11B +$14.4M $20.93 112
2020 Q1 52M $725M +$12.4M $13.95 99
2019 Q4 51.1M $1.16B +$87.9M $22.76 115
2019 Q3 43.3M $504M -$33.1M $11.65 88
2019 Q2 47M $705M +$95.7M $15.00 93
2019 Q1 39.9M $699M +$16.5M $17.54 78
2018 Q4 38.6M $570M +$71.2M $14.82 82
2018 Q3 33.8M $832M +$69.9M $24.62 80
2018 Q2 31.1M $605M +$63.9M $19.63 75
2018 Q1 28M $502M +$502M $18.75 55